NCT00122343 - AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Endometrial Cancer

Interventions

DRUG

ridaforolimus

AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.